IL325937A - נוגדנים המועברים על ידי aav ושיטות לשימוש בהם - Google Patents

נוגדנים המועברים על ידי aav ושיטות לשימוש בהם

Info

Publication number
IL325937A
IL325937A IL325937A IL32593726A IL325937A IL 325937 A IL325937 A IL 325937A IL 325937 A IL325937 A IL 325937A IL 32593726 A IL32593726 A IL 32593726A IL 325937 A IL325937 A IL 325937A
Authority
IL
Israel
Prior art keywords
aav
methods
delivered antibodies
antibodies
delivered
Prior art date
Application number
IL325937A
Other languages
English (en)
Original Assignee
Univ Miami
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami, Univ California filed Critical Univ Miami
Publication of IL325937A publication Critical patent/IL325937A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL325937A 2023-07-24 2024-07-24 נוגדנים המועברים על ידי aav ושיטות לשימוש בהם IL325937A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363515218P 2023-07-24 2023-07-24
PCT/US2024/039323 WO2025024541A2 (en) 2023-07-24 2024-07-24 Aav-delivered antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
IL325937A true IL325937A (he) 2026-03-01

Family

ID=94375705

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325937A IL325937A (he) 2023-07-24 2024-07-24 נוגדנים המועברים על ידי aav ושיטות לשימוש בהם

Country Status (2)

Country Link
IL (1) IL325937A (he)
WO (1) WO2025024541A2 (he)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350245B2 (en) * 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2020097252A1 (en) * 2018-11-06 2020-05-14 University Of Miami Compositions and production of recombinant aav viral vectors capable of glycoengineering in vivo
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection
CN119173251A (zh) * 2022-04-29 2024-12-20 库尔制药开发公司 用于克服治疗性载体和蛋白质的免疫原性的耐受性免疫修饰纳米粒子

Also Published As

Publication number Publication date
WO2025024541A3 (en) 2025-04-17
WO2025024541A2 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
IL316368A (he) נוגדנים אנטי- tl1a ושיטות לשימוש בהם
SMT202500106T1 (it) Anticorpi anti-par-2 e loro metodi d'uso
IL315845A (he) נוגדנים אנטי-דקטין-1 ושיטות לשימוש בהם
IL298668B1 (he) נוגדנים נגד cd200r1 ושיטות לשימוש בהם
IL319590A (he) נוגדנים רב-ספציפיים ושיטות לשימוש בהם
IL316065A (he) נוגדנים אנטי- cd28ושיטות לשימוש בהם
IL317690A (he) נוגדנים אנטי- gpnmbושיטות לשימוש בהם
IL318694A (he) נוגדנים כנגד ccr8 ושיטות לשימוש בהם
IL308260A (he) נוגדנים נגד טיגיט ודרכי השימוש בהם
IL325937A (he) נוגדנים המועברים על ידי aav ושיטות לשימוש בהם
IL318357A (he) נוגדני anti-il27r ושיטות השימוש בהם
IL316700A (he) נוגדני anti-bmp9 ושיטות השימוש בהם
IL316894A (he) נוגדני anti-tnfr2 ושיטות השימוש בהם
IL321679A (he) נוגדני אנטי-ror2 ושיטות לשימוש
IL310551A (he) נוגדנים חד-שבטיים ספציפיים ל-osmr ושיטות השימוש בהם
IL311003A (he) נוגדנים אנטי-2her ושיטות שימוש בהם
IL325840A (he) נוגדני pd-l1xcd28 דו-ספציפיים ושיטות שימוש בהם
IL325837A (he) נוגדני pd-l1x4-1bb דו-ספציפיים ושיטות שימוש בהם
GB202204813D0 (en) Human monoclonal antibodies and methods of use thereof
GB202204736D0 (en) Human monoclonal antibodies and methods of use thereof
CA3303930A1 (en) Anti-nectin-4 antibodies and methods of use thereof
CA3298139A1 (en) Aav-delivered antibodies and methods of use thereof
CA3292076A1 (en) Anti-toh1 antibodies and methods of use thereof
CA3286084A1 (en) Anti-cd161 antibodies and methods of use thereof